web
counter
Call us toll-free at 1-855-420-7140

Scientific Papers

ColonSentry®

Peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool Journal of Laboratory and Clinical Medicine. 2006;147:126-32.Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA

Blood RNA Biomarker Panel Detects Both Left- and Right-sided Colorectal NeoplasmsNext Generation Dx Summit (2010) Poster;Chao S, Ying J, Liew G, et al.

A case-controlled validation study of a bloodbased seven-gene biomarker panel for colorectal cancer in Malaysia Journal of Experimental & Clinical Cancer Research: 29, 128 (2010), Yip KT, Das P, Suria D, et

A blood-based biomarker panel for stratifying current risk for colorectal cancer International Journal of Cancer: 126, 1177

EarlyCDT®-Lung

2014

Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW and Robertson JFR.  Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients:  An evaluation of its performance in routine clinical practice.  Lung Cancer 2014;83:51-55.

August 5, Serum Autoantibody Measurement for the Detection of Hepatocellular Carcinoma; PLOS ONE 

2013
October 29, Application of a High Throughput Method of Biomarker Discovery to Improvement of the EarlyCDT®-Lung Test; PLOS ONE

October 14, Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice; Lung Cancer 

August 23, Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer; Journal of Thoracic Disease Full article

2012
Murray A, Fritsche HA, Wood WC, Hamilton-Fairley G & Robertson JF (2012) Challenges in Biomarker Development and Validation. In: Boyle P, Autier P, Adebamowo C, Anderson B, Pinillos Aston L, Badwe RA & Yamaguchi N. (Eds) World Breast Cancer Report 2012. International Prevention Research Institute, Lyon, France. ISBN: 978-2-9539268-1-1. Abstract. Link to Executive Summary

July 12, Development and Validation of a High Throughput System for Discovery of Antigens for Autoantibody Detection; PLOS ONE 

2011
July 7 World Congress for Lung Cancer (WCLC) in Amsterdam Meeting Poster EarlyCDT-Lung Test: Audit of the First 1000 Patients in Clinical Practice 

Prostate Health Index (PHI)

Improving the Prediction of Pathologic Outcomes in Patients Undergoing Radical Prostatectomy: The Value of Prostate Cancer Antigen 3 (PCA3), Prostate Health Index (Phi) and Sarcosine PHI PCA3 Sarcosine 2015 Path Outcomes in RP

Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer
Antigen 3 in predicting pathologic features after radical prostatectomy. Urol Oncol 2015 Jan 6. pii: S1078-1439(14)00448-7.doi: 10.1016/j.urolonc.2014.12.002.PHI vs PCA3 Urol Oncol 2015 Jan 6

A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate
Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. Journal of Urology, 2011

Evaluation of [ − 2] proPSA and Prostate HealthIndex (phi) for the detection of prostate cancer:
a systematic review and meta-analysis; DOI 10.1515/cclm-2012-0410 Clin Chem Lab Med 2012; aop Filella phi Review Meta analysis CCLM 2012

The Prostate Health Index: a new test for thedetection of prostate cancer, Stacy Loeb and William J. Catalona, PHI a New PCa Test Catalona-Loeb 2014

BreastSentry

Melander O, Belting M, Manjer J, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1672-6.

Melander O, Orho-Melander M, Manjer J, et al. Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk. J Clin Oncol. 2015 Aug 20;33(24):2632-8

Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011;93:1369–78

Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 2012;308:1469–75.